Literature DB >> 23053139

Late complications after radiotherapy for prostate cancer.

H Jung1, H-P Beck-Bornholdt, V Svoboda, W Alberti, T Herrmann.   

Abstract

BACKGROUND: The aim of the present study was to analyze in detail the time course of the incidence of radiation-induced late effects. For this purpose, unpublished data of patients treated by radiation therapy in Hamburg in the late 1980s were analyzed. Relatively large volumes were exposed to comparatively high doses, thus leading to a high rate of treatment-related side effects. PATIENTS AND METHODS: A total of 180 consecutive patients received radiotherapy for prostate cancer. The median age was 66 years (range 41-88 years). The median of the maximum dose was 77.5 Gy (range 56.3-95 Gy) and overall treatment time was 51 days (range 28-128 days). Endpoints analyzed were late complications of grade 3 or higher, overall and disease-free survival, local tumor control, and distant metastases. Data analysis was actuarial and the log-rank test was used to compare the various subgroups.
RESULTS: After 2 years, 80.5 ± 3.2% of the patients were without any complications of grade 3 or higher, and after 5 years a constant level of 70.3 ± 4.0% was approached. When multiple lesions occurred per patient, the later events were disregarded. A total of 66 complications occurred in 42 patients. The percentage of patients being free from late complications, plotted as a function of time after start of radiation therapy, was adequately described by an exponential function and a constant fraction. Complications approached a constant level of 70.3% at a rate of 5.3% per month. This means that patients who will develop a complication do so at exponential kinetics and at a relatively high rate, whereas about 70% of the patients will never experience a late effect even over long observation periods. After subdividing the maximum dose into three equal dose groups of 55 patients each (< 73.3 Gy, 73.3-80 Gy, > 80 Gy), the constant fraction decreased from 85.7 to 72.8% and 52.2%, whereas the incidence rate was 4.3%, 7.7%, and 5.6% per month and, thus, almost independent of radiation dose.
CONCLUSION: For a given group of patients, the rate of the incidence of late complications appears to be independent of radiation dose and (from analyzing data in the literature) independent of the grade of lesions, whereas the fraction of patients without late effects depends on both parameters.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23053139     DOI: 10.1007/s00066-012-0142-z

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  17 in total

1.  Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer.

Authors:  Zumre A Alicikus; Yoshiya Yamada; Zhigang Zhang; Xin Pei; Margie Hunt; Marisa Kollmeier; Brett Cox; Michael J Zelefsky
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

2.  Long-term results of a prospective, Phase II study of long-term androgen ablation, pelvic radiotherapy, brachytherapy boost, and adjuvant docetaxel in patients with high-risk prostate cancer.

Authors:  Steven J Dibiase; Arif Hussain; Ritesh Kataria; Pradip Amin; Sunakshi Bassi; Nancy Dawson; Young Kwok
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-30       Impact factor: 7.038

3.  Intensity-modulated radiotherapy reduces gastrointestinal toxicity in patients treated with androgen deprivation therapy for prostate cancer.

Authors:  Navesh K Sharma; Tianyu Li; David Y Chen; Alan Pollack; Eric M Horwitz; Mark K Buyyounouski
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-11-02       Impact factor: 7.038

4.  Do intermediate radiation doses contribute to late rectal toxicity? An analysis of data from radiation therapy oncology group protocol 94-06.

Authors:  Susan L Tucker; Lei Dong; Jeff M Michalski; Walter R Bosch; Kathryn Winter; James D Cox; James A Purdy; Radhe Mohan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-02-17       Impact factor: 7.038

5.  Impact of VEGF gene polymorphisms and haplotypes on radiation-induced late toxicity in prostate cancer patients.

Authors:  Tanja Langsenlehner; Wilfried Renner; Armin Gerger; Günter Hofmann; Eva-Maria Thurner; Karin S Kapp; Uwe Langsenlehner
Journal:  Strahlenther Onkol       Date:  2011-11-17       Impact factor: 3.621

6.  Late gastrointestinal toxicities following radiation therapy for prostate cancer.

Authors:  Sung Kim; Shunhua Shen; Dirk F Moore; Weichung Shih; Yong Lin; Hui Li; Matthew Dolan; Yu-Hsuan Shao; Grace L Lu-Yao
Journal:  Eur Urol       Date:  2011-06-12       Impact factor: 20.096

7.  Late complications after a combined pre and postoperative (sandwich) radiotherapy for rectal cancer.

Authors:  V Svoboda; H P Beck-Bornholdt; T Herrmann; W Alberti; H Jung
Journal:  Radiother Oncol       Date:  1999-12       Impact factor: 6.280

8.  Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer.

Authors:  Eugene H Huang; Alan Pollack; Larry Levy; George Starkschall; Lei Dong; Isaac Rosen; Deborah A Kuban
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-12-01       Impact factor: 7.038

9.  Late rectal toxicity after conformal radiotherapy of prostate cancer (I): multivariate analysis and dose-response.

Authors:  M W Skwarchuk; A Jackson; M J Zelefsky; E S Venkatraman; D M Cowen; S Levegrün; C M Burman; Z Fuks; S A Leibel; C C Ling
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-04-01       Impact factor: 7.038

10.  Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study.

Authors:  Jeff M Michalski; Kyounghwa Bae; Mack Roach; Arnold M Markoe; Howard M Sandler; Janice Ryu; Matthew B Parliament; William Straube; Richard K Valicenti; James D Cox
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-01-01       Impact factor: 7.038

View more
  3 in total

1.  Dependence of the safe rectum dose on the CTV-PTV margin size and treatment technique.

Authors:  Pawel Kukołowicz; Helena Kukołowicz; Izabela Tyburska
Journal:  Rep Pract Oncol Radiother       Date:  2015-01-07

2.  Protocol-based image-guided salvage brachytherapy. Early results in patients with local failure of prostate cancer after radiation therapy.

Authors:  G Lahmer; M Lotter; S Kreppner; R Fietkau; V Strnad
Journal:  Strahlenther Onkol       Date:  2013-07-05       Impact factor: 3.621

3.  Association of genetic variants in apoptosis genes FAS and FASL with radiation-induced late toxicity after prostate cancer radiotherapy.

Authors:  E-M Thurner; S Krenn-Pilko; U Langsenlehner; W Renner; A Gerger; K S Kapp; T Langsenlehner
Journal:  Strahlenther Onkol       Date:  2014-01-16       Impact factor: 3.621

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.